Live Breaking News & Updates on Cerebrospinal

Stay updated with breaking news from Cerebrospinal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Middle-aged mum Jana Nelson opens up about 'devastating' dementia diagnosis

Five years after undergoing lifesaving surgery for congenital hydrocephalus - a neurological disorder caused by an abnormal build-up of cerebrospinal fluid. ....

United States , Jana Nelson , Daily Mail ,

MyJournals.org - Science - 'Anti-N-methyl-d-aspartate receptor encephalitis and positive human herpesvirus-7 deoxyribonucleic acid in cerebrospinal fluid: a case report' (Journal of Medical Case Reports)

MyJournals.org - Science - Anti-N-methyl-d-aspartate receptor encephalitis and positive human herpesvirus-7 deoxyribonucleic acid in cerebrospinal fluid: a case report (Journal of Medical Case Reports) ....

Medical Case Reports , Ntin Methyld Aspartate , Erpesvirus 7 ,

Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer's Disease and Cerebral Amyloid Angiopathy

- Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date - - Encouraging. | April 26, 2023 ....

United Kingdom , United States , Pushkal Garg , Alexandra Bowie , Christine Regan Lindenboom , Yvonne Greenstreet , Georged Yancopoulos , Bryan Crowe , Regeneron Genetics Center , Alnylam Pharmaceuticals , Exchange Commission , Alnylam Pharmaceuticals Inc , Regeneron Pharmaceuticals Inc , Securities Exchange , Sustained Reduction , Cerebrospinal Fluid , Highest Dose , Clinical Safety , Tolerability Profile Observed , Single Dosing , Provide First Demonstration , Gene Silencing , Human Brain Using Alnylam , Chief Medical Officer , Chief Executive Officer , Chief Scientific Officer ,

Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer's Disease and Cerebral Amyloid Angiopathy

– Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date. | April 26, 2023 ....

United States , United Kingdom , Yvonne Greenstreet , Georged Yancopoulos , Pushkal Garg , Alnylam Pharmaceuticals Inc , Exchange Commission , Regeneron Pharmaceuticals Inc , Regeneron Pharmaceuticals , Securities Exchange , Regeneron Genetics Center , Alnylam Pharmaceuticals , Chief Medical Officer , Chief Executive Officer , Chief Scientific Officer , Call Information , Cerebral Amyloid Angiopathy , Nobel Prize Winning , Forward Looking Statements , Securities Act , Securities Exchange Act , Quarterly Reports , Digital Media , Product Candidates , Nc Stock Exchange , Press Release ,

Tiny Channels Discovered Inside The Human Skull Could Be Vital For The Brain

A shortcut between the skull and the brain could be a possible way for the human immune system to bypass the blood-brain barrier. ....

Harvard University , United States , Matthias Nahrendorf , Nature Neuroscience , Massachusetts General Hospital , Mp Quot ,